Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel

Reuters07-08

Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> in Israel

Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2549547479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549547479","market":"nz","top_or_hot":-1,"title":"Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> in Israel\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic <a href=\"https://laohu8.com/S/CTHZ\">Cancer Treatment</a> in Israel\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL69MZ4X:1","article_id":"2549547479","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549547479","pubTimestamp":1751979633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps  in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XBIO":"Xenetic Biosciences Inc"},"translate_title":"Xenetic Biosciences宣布在以色列启动DNase I治疗胰腺癌的探索性临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBIO":0.9},"content_text":"Xenetic Biosciences Announces Initiation of Exploratory Clinical Study on DNase I for Pancreatic Cancer Treatment in Israel\n    \n\n        Xenetic Biosciences, Inc. has announced that its collaboration partner, PeriNess Ltd., has initiated patient dosing in an exploratory clinical study at Bnei Zion Medical Center in Israel. The study is investigating the use of systemic recombinant human DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer. Dr. Abed Agbabrya, head of Oncology at Bnei Zion Hospital, is the principal investigator. The study aims to explore the potential of DNase I to improve treatment outcomes by degrading neutrophil extracellular traps (NETs) in the pancreatic cancer tumor microenvironment. Results from this study have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046466) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549547479","isCrawlerRequest":true}